The second echelon includes C3 (CML), which contains imatinib, dasatinib, BCR-ABL, nilotinib, gastrointestinal stromal tumor, etc.; C4 (HER2), which contains apoptosis, breast cancer, lapatinib, autophagy, combination therapy, etc.; and C5 (pharmacokinetics), which contains ibrutinib, metabolism, molecular docking, plasma, drug-drug interaction, etc. These 3 communities are involved in research topics that are also important for TKIs research. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.